Aon Says 2027 Health Premiums Will Squeeze Employers

Consulting and brokerage firm Aon confirmed that 2027 will be a brutal year for job-based health care premiums, with its chief actuary saying in a news release that employers will need to respond; Aon shares last closed at 359.10, up 1.12% on Aug. 24, 2026.

Aon, one of the largest insurance brokers and benefits consultants in the world, has told employers what many of their finance chiefs already suspected: 2027 will be a brutal year for job-based health care premiums. The firm's chief actuary framed the message around what companies will have to do next, saying in a news release that "Employers will need" to act — a phrase that, in benefits language, almost always ends in higher payroll deductions, tighter networks or thinner coverage.

The warning matters because employer-sponsored insurance is the single largest source of coverage in the United States. When brokers of Aon's size publish a directional call on next year's renewals, that call becomes the anchor for thousands of budget conversations that begin in the autumn and end in open enrollment.

Why a broker's premium call carries weight

Aon does not simply forecast health costs; it sits in the middle of the transaction. The firm advises large employers on plan design, negotiates with carriers on their behalf, and runs the actuarial models that translate medical claims trends into a renewal number. A statement from its chief actuary is therefore closer to a pricing signal than a piece of commentary.

For employers, the mechanics are unforgiving. Premiums for a self-funded or fully insured plan are built from claims experience, provider unit prices, drug spend and administrative load. When any of those legs move, the employer has three levers: absorb the increase, pass it to workers through higher contributions and deductibles, or change what the plan covers. Most large employers use some blend of all three, and the mix is decided in exactly the window the industry is entering now.

What is different about the current cycle is the composition of the pressure. Specialty pharmacy, hospital consolidation and higher-acuity utilization have all been cited across the benefits industry as structural rather than temporary drivers. Structural cost growth is the kind that survives a single year of plan-design tinkering, which is why a warning about 2027 is being read as a warning about the years after it too.

Public-sector plans are the hardest to fix

The most exposed employers are not necessarily the largest — they are the least flexible. Public-sector health plans, covering teachers, municipal staff, transit workers and state employees, sit inside collectively bargained agreements and legislated budgets. A private employer can redesign a plan for the following January. A school district or a state health plan often cannot, because the benefit is a term of a contract and the money comes from an appropriation set months earlier.

That produces what amounts to a squeeze with no valve. Costs rise on the medical side while the revenue side is fixed by a tax base, and the benefit itself is legally difficult to trim. The predictable result is a bargaining-table fight: employers seek cost-sharing changes, unions defend the coverage they traded wage increases for, and the dispute lands in impasse procedures rather than a benefits committee.

The union-hospital conflict referenced alongside Aon's numbers by STAT News is the other half of the same equation. Hospitals are both providers whose prices drive premiums and large employers whose own workers are unionized. A health system negotiating higher commercial rates with insurers while simultaneously arguing with its nurses over their own health benefits is a fair summary of where the American cost conversation now sits.

What employers typically do when renewals come in high

The playbook is well established, and it is worth spelling out because it determines who actually pays the increase. Common responses to a hard renewal include:

• Higher employee contributions. The fastest lever, and the most visible on a paycheck.
• Higher deductibles and out-of-pocket maximums. Keeps the headline premium down while shifting risk to workers who get sick.
• Narrow or tiered networks. Cheaper unit prices in exchange for fewer in-network hospitals — the point where employer strategy collides directly with health-system revenue.
• Tighter specialty drug management. Prior authorization, site-of-care steering and formulary exclusions, increasingly aimed at the highest-cost therapies.
• Plan consolidation. Fewer options, with the richest tier priced to discourage enrollment.

None of these reduce medical costs in the system. They reallocate them. For workers, the practical effect of a brutal renewal year is usually not the loss of insurance but the erosion of what the insurance does when it is used.

Where Aon shares stand

Aon's own market position is the mirror image of the problem it is describing. Rising and more complex health costs increase demand for the advice, brokerage and actuarial work the firm sells. AON last closed at 359.10, up 1.12% on the day, with a session range of 356.50 to 361.73 and a previous close of 355.11, as of the last trade on Aug. 24, 2026.

That gain came against a mixed tape. The S&P 500, via the SPY exchange-traded fund, closed at $763.47, down 0.29%, while the Nasdaq 100 tracker QQQ fell 1.00% to $706.32. The Dow 30 proxy DIA was the exception, up 0.27% at $533.65. In other words, the broker gained ground on a session when the broad market lost some, and the technology-heavy index lost more.

What to watch through renewal season

Three markers will show whether Aon's call is landing. First, the disclosure trail: large employers that guide on benefits expense will begin quantifying 2027 assumptions in the coming quarters, and those assumptions are checkable against the broker's directional view. Second, public-sector bargaining. Watch for impasse filings and arbitration in state and municipal plans, which are the earliest visible sign that cost-sharing changes are being forced rather than negotiated. Third, the hospital-insurer contract cycle, where every rate increase agreed in 2026 becomes an employer premium in 2027.

For biotech and pharmaceutical companies, the second-order risk is utilization management. When employers face a hard renewal, specialty drug spend is among the first line items reviewed, and the tools used — exclusions, step therapy, site-of-care restrictions — bear directly on the commercial ramp of high-priced therapies. A brutal premium year for employers tends to become a slower launch year for whoever is selling the most expensive medicines.

Key facts

• AON last close: 359.10, +1.12% on the day (as of Aug. 24, 2026, 20:00 GMT)
• Aon's 2027 call: Job-based health care premiums set for a brutal year
• AON day range: 356.50–361.73, prev close 355.11
• Market backdrop: SPY $763.47 (-0.29%), QQQ $706.32 (-1.00%), DIA $533.65 (+0.27%)

Frequently asked questions

What did Aon actually say about 2027 health premiums?

Aon, a large consulting and insurance brokerage house, confirmed that 2027 will be a brutal year for job-based health care premiums. Its chief actuary said in the company's news release that employers will need to respond, though the full quotation was truncated in reporting. Aon advises large employers on plan design and negotiates with carriers, so the statement functions as a pricing signal.

Who is most exposed to a hard 2027 renewal?

Public-sector employers such as school districts, municipalities and state health plans are the most constrained. Their benefits are set in collectively bargained contracts and funded through appropriations fixed months in advance, so they cannot redesign coverage quickly. That combination tends to push disputes into bargaining, impasse procedures or arbitration rather than routine benefits committees.

How do employers usually respond to steep premium increases?

The standard levers are higher employee contributions, higher deductibles and out-of-pocket maximums, narrower or tiered provider networks, tighter management of specialty drugs through prior authorization and formulary exclusions, and consolidation of plan options. None of these reduce underlying medical costs; they reallocate who pays them, usually toward workers who actually use care.

Why is a union-hospital fight part of this story?

Hospitals sit on both sides of the cost equation. They are providers whose negotiated commercial rates feed directly into next year's employer premiums, and they are large, often unionized employers arguing with their own staff over health benefits. A dispute between a union and a health system therefore captures the provider-price and worker-cost halves of the same problem.

How did Aon shares trade on the day of the warning?

AON last closed at 359.10, a gain of 1.12% from a previous close of 355.11, with a session range of 356.50 to 361.73, as of the last trade at 20:00 GMT on Aug. 24, 2026. That advance came on a day when the S&P 500 tracker SPY fell 0.29% and the Nasdaq 100 tracker QQQ fell 1.00%.

What does this mean for drugmakers and biotech companies?

Specialty pharmacy spend is typically among the first items employers review when a renewal comes in high. The resulting utilization-management tools — step therapy, prior authorization, site-of-care steering and formulary exclusions — bear directly on how quickly high-priced therapies gain commercial traction, making a hard premium year a potential headwind for new launches.

Sources

• STAT+: Public-sector purgatory, and a union-hospital fight — STAT News

Photo: RDNE Stock project · Pexels Licence — source